GLP-1 receptor agonist medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, produce significant weight loss. The face does not lose weight selectively. As the body mobilizes fat stores, the fat pads that give the face its youthful structure deplete alongside fat elsewhere.
The result, widely called "Ozempic face," is facial hollowing, accelerated skin laxity, deepened under-eye hollows, and gaunt cheeks. The treatment that most directly addresses this is autologous fat transfer, returning the patient's own harvested fat to the exact compartments that were depleted.
Dr. Whitfield's published research in the Aesthetic Surgery Journal (PMID 29044365) addresses fat-grafting safety outcomes, a credential no Austin med spa or dermatology practice brings to this procedure.
The national guide explains causes, treatment options, and the fat transfer process. Review the complete guide to Ozempic face treatment.